Journal article
Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease
Kidney international, Vol.99(2), pp.466-474
02/2021
DOI: 10.1016/j.kint.2020.08.011
PMCID: PMC7957958
PMID: 32920022
Abstract
The role of aspirin for primary prevention in older adults with chronic kidney disease (CKD) is unclear. Therefore, post hoc analysis of the randomized controlled trial ASPirin in Reducing Events in the Elderly (ASPREE) was undertaken comparing 100 mg of enteric-coated aspirin daily against matching placebo. Participants were community dwelling adults aged 70 years and older in Australia, 65 years and older in the United States, all free of a history of dementia or cardiovascular disease and of any disease expected to lead to death within five years. CKD was defined as present at baseline if either eGFR under 60mL/min/1.73m2 or urine albumin to creatinine ratio 3 mg/mmol or more. In 4758 participants with and 13004 without CKD, the rates of a composite endpoint (dementia, persistent physical disability or death), major adverse cardiovascular events and clinically significant bleeding in the CKD participants were almost double those without CKD. Aspirin’s effects as estimated by hazard ratios were generally similar between CKD and non-CKD groups for dementia, persistent physical disability or death, major adverse cardiovascular events and clinically significant bleeding. Thus, in our analysis aspirin did not improve outcomes in older people while increasing the risk of bleeding, with mostly consistent effects in participants with and without CKD.
[Display omitted]
Details
- Title: Subtitle
- Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease
- Creators
- Rory Wolfe - Monash UniversityJames B. Wetmore - Hennepin Healthcare Research InstituteRobyn L. Woods - Monash UniversityJohn J. McNeil - Monash UniversityHugh Gallagher - Epsom and St Helier University Hospitals NHS TrustPaul Roderick - Southampton General HospitalRowan Walker - Monash UniversityMark R. Nelson - University of TasmaniaChristopher M. Reid - Monash UniversityRaj C. Shah - Rush University Medical CenterMichael E. Ernst - University of IowaJessica E. Lockery - Monash UniversityAndrew M. Tonkin - Monash UniversityWalter P. Abhayaratna - Australian National UniversityPeter Gibbs - Walter and Eliza Hall Institute of Medical ResearchErica M. Wood - Monash UniversitySuzanne E. Mahady - Monash UniversityJeff D. Williamson - Wake Forest UniversityGeoffrey A. Donnan - The Royal Melbourne HospitalGeoffrey C. Cloud - Monash UniversityAnne M. Murray - Hennepin Healthcare Research InstituteKevan R. Polkinghorne - Monash University
- Resource Type
- Journal article
- Publication Details
- Kidney international, Vol.99(2), pp.466-474
- DOI
- 10.1016/j.kint.2020.08.011
- PMID
- 32920022
- PMCID
- PMC7957958
- NLM abbreviation
- Kidney Int
- ISSN
- 0085-2538
- eISSN
- 1523-1755
- Publisher
- Elsevier Inc
- Grant note
- DOI: 10.13039/501100000925, name: National Health and Medical Research Council; DOI: 10.13039/100000049, name: National Institute on Aging
- Language
- English
- Date published
- 02/2021
- Academic Unit
- Family and Community Medicine; Pharmacy Practice and Science
- Record Identifier
- 9984297456402771
Metrics
11 Record Views